Supplementary Figures from Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Year: 2023
Type: supplementary-materials
Authors: Teeru Bihani, Hitisha K. Patel, Heike Arlt, Nianjun Tao, Hai Jiang, Jeffrey L. Brown, Dinesh M. Purandare, Gary Hattersley, Fiona Garner
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361885151